Cargando…

Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs

Natural Killer (NK) cells target oral, pancreatic, lung, breast, glioblastoma and melanoma stem-like/poorly differentiated tumors. Differentiation of the abovementioned tumors with supernatants from split-anergized NK cells decreases their susceptibility to NK cells, but increases their sensitivity...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozlowska, Anna Karolina, Topchyan, Paytsar, Kaur, Kawaljit, Tseng, Han-Ching, Teruel, Antonia, Hiraga, Toru, Jewett, Anahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370498/
https://www.ncbi.nlm.nih.gov/pubmed/28367234
http://dx.doi.org/10.7150/jca.15989
_version_ 1782518251110006784
author Kozlowska, Anna Karolina
Topchyan, Paytsar
Kaur, Kawaljit
Tseng, Han-Ching
Teruel, Antonia
Hiraga, Toru
Jewett, Anahid
author_facet Kozlowska, Anna Karolina
Topchyan, Paytsar
Kaur, Kawaljit
Tseng, Han-Ching
Teruel, Antonia
Hiraga, Toru
Jewett, Anahid
author_sort Kozlowska, Anna Karolina
collection PubMed
description Natural Killer (NK) cells target oral, pancreatic, lung, breast, glioblastoma and melanoma stem-like/poorly differentiated tumors. Differentiation of the abovementioned tumors with supernatants from split-anergized NK cells decreases their susceptibility to NK cells, but increases their sensitivity to cisplatin (CDDP)-mediated cell death. Breast and melanoma tumor cells with CD44 knockdown display enhanced susceptibility to NK cell-mediated lysis, potentially due to decreased differentiation. We also demonstrate that sulindac, a non-steroidal anti-inflammatory drug and a chemopreventive agent, not only limits the growth of oral tumor cells, but also aids in cancer cell elimination by NK cells. Treatment of oral tumors with sulindac, but not adriamycin inversely modulates the expression and function of NFκB and JNK, resulting in a significant down-regulation of IL-6, and VEGF secretion by oral tumor cells. In addition, increased secretion of IL-6 and VEGF is blocked by sulindac during interaction of oral tumors with NK cells. Sulindac treatment prevents synergistic induction of VEGF secretion by the tumor cells after their co-culture with untreated NK cells since non-activated NK cells lack the ability to efficiently kill tumor cells. Moreover, sulindac is able to profoundly reduce VEGF secretion by tumor cells cultured with IL-2 activated NK cells, which are able to significantly lyse the tumor cells. Based on the data presented in this study, we propose the following combinatorial approach for the treatment of stem-like/ poorly differentiated tumors in cancer patients with metastatic disease. Stem-like/ poorly differentiated tumor cells may in part undergo lysis or differentiation after NK cell immunotherapy, followed by treatment of differentiated tumors with chemotherapy and chemopreventive agents to eliminate the bulk of the tumor. This dual approach should limit tumor growth and prevent metastasis.
format Online
Article
Text
id pubmed-5370498
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-53704982017-03-31 Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs Kozlowska, Anna Karolina Topchyan, Paytsar Kaur, Kawaljit Tseng, Han-Ching Teruel, Antonia Hiraga, Toru Jewett, Anahid J Cancer Research Paper Natural Killer (NK) cells target oral, pancreatic, lung, breast, glioblastoma and melanoma stem-like/poorly differentiated tumors. Differentiation of the abovementioned tumors with supernatants from split-anergized NK cells decreases their susceptibility to NK cells, but increases their sensitivity to cisplatin (CDDP)-mediated cell death. Breast and melanoma tumor cells with CD44 knockdown display enhanced susceptibility to NK cell-mediated lysis, potentially due to decreased differentiation. We also demonstrate that sulindac, a non-steroidal anti-inflammatory drug and a chemopreventive agent, not only limits the growth of oral tumor cells, but also aids in cancer cell elimination by NK cells. Treatment of oral tumors with sulindac, but not adriamycin inversely modulates the expression and function of NFκB and JNK, resulting in a significant down-regulation of IL-6, and VEGF secretion by oral tumor cells. In addition, increased secretion of IL-6 and VEGF is blocked by sulindac during interaction of oral tumors with NK cells. Sulindac treatment prevents synergistic induction of VEGF secretion by the tumor cells after their co-culture with untreated NK cells since non-activated NK cells lack the ability to efficiently kill tumor cells. Moreover, sulindac is able to profoundly reduce VEGF secretion by tumor cells cultured with IL-2 activated NK cells, which are able to significantly lyse the tumor cells. Based on the data presented in this study, we propose the following combinatorial approach for the treatment of stem-like/ poorly differentiated tumors in cancer patients with metastatic disease. Stem-like/ poorly differentiated tumor cells may in part undergo lysis or differentiation after NK cell immunotherapy, followed by treatment of differentiated tumors with chemotherapy and chemopreventive agents to eliminate the bulk of the tumor. This dual approach should limit tumor growth and prevent metastasis. Ivyspring International Publisher 2017-02-11 /pmc/articles/PMC5370498/ /pubmed/28367234 http://dx.doi.org/10.7150/jca.15989 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Kozlowska, Anna Karolina
Topchyan, Paytsar
Kaur, Kawaljit
Tseng, Han-Ching
Teruel, Antonia
Hiraga, Toru
Jewett, Anahid
Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs
title Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs
title_full Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs
title_fullStr Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs
title_full_unstemmed Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs
title_short Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs
title_sort differentiation by nk cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370498/
https://www.ncbi.nlm.nih.gov/pubmed/28367234
http://dx.doi.org/10.7150/jca.15989
work_keys_str_mv AT kozlowskaannakarolina differentiationbynkcellsisaprerequisiteforeffectivetargetingofcancerstemcellspoorlydifferentiatedtumorsbychemopreventiveandchemotherapeuticdrugs
AT topchyanpaytsar differentiationbynkcellsisaprerequisiteforeffectivetargetingofcancerstemcellspoorlydifferentiatedtumorsbychemopreventiveandchemotherapeuticdrugs
AT kaurkawaljit differentiationbynkcellsisaprerequisiteforeffectivetargetingofcancerstemcellspoorlydifferentiatedtumorsbychemopreventiveandchemotherapeuticdrugs
AT tsenghanching differentiationbynkcellsisaprerequisiteforeffectivetargetingofcancerstemcellspoorlydifferentiatedtumorsbychemopreventiveandchemotherapeuticdrugs
AT teruelantonia differentiationbynkcellsisaprerequisiteforeffectivetargetingofcancerstemcellspoorlydifferentiatedtumorsbychemopreventiveandchemotherapeuticdrugs
AT hiragatoru differentiationbynkcellsisaprerequisiteforeffectivetargetingofcancerstemcellspoorlydifferentiatedtumorsbychemopreventiveandchemotherapeuticdrugs
AT jewettanahid differentiationbynkcellsisaprerequisiteforeffectivetargetingofcancerstemcellspoorlydifferentiatedtumorsbychemopreventiveandchemotherapeuticdrugs